Background: The integrated evaluation of traditional and innovative red blood cell (RBC) and reticulocyte parameters is a rapid, inexpensive and non-invasive diagnostic tools for differential diagnosis and follow-up of anemia and other pathological conditions needing bone marrow erythropoiesis assessment. Therefore, estimating the biological variation (BV) of these parameters is essential for evaluating the analytical performance of hematological analyzers, and for enabling accurate data interpretation and appropriate clinical management. This study aims to define short-and medium-term BV estimates and reference change value (RCV) of RBC and reticulocyte parameters. Methods: Twenty-one healthy volunteers participated in the assessment of medium-term BV (blood sampling once/week, five consecutive weeks) and 22 volunteers in the assessment of short-term BV (blood sampling once/ day, five consecutive days) using Sysmex XN. Outlier analysis was performed before CV-ANOVA, to determine BV estimates with confidence intervals (CI). Results: Medium-and short-term within-subject BV were between 0.3% and 16.4% and 0.2%-10.4% (MCH and IRF), respectively, whereas medium and short-term betweensubjects BV ranged between 0.9% and 66.6% (MCHC and 
Introduction
Anemia is one of the most widespread pathological conditions worldwide, often caused by nutritional deficiencies or bad eating habits, irrespective of development of the host's economy [1] [2] [3] . The complete blood cell count (CBC), combined with reticulocyte (RET) count [4] , are still the gold standard for the diagnosis of anemia.
The latest generation of hematological analyzers has allowed the development of an innovative approach for identifying the underlying causes of anemia, based on integration of conventional hematological parameters such as hemoglobin (Hb) and Wintrobe indices (e.g. mean corpuscular volume [MCV] , mean corpuscular hemoglobin concentration [MCHC] and mean corpuscular hemoglobin [MCH] [4, 5] ) with new red blood cell (RBC) and RET parameters. Modern instrumentation can actually generate a remarkable number of erythrocyte parameters, such as the range of variation of RBC volume expressed either as the standard deviation (SD) or coefficient of variation (CV%) of the RBC distribution width (RDW), the percentage of hypochromic, hyperchromic, microcytic and macrocytic erythrocytes, along with fullyautomated RET counting [6] [7] [8] . This last measurement allows to classify RET into different classes of maturation, thus including immature RET fraction (IRF) and, depending on the analytical technology, in low (LRF), medium (MRF) and high fluorescence reticulocytes (HFR) cells. Some of the latest generation of hematological analyzers can also efficiently measure the mean RET hemoglobin content (RET-He), the mean RET volume, along with the RET production index (RPI) [4, 8] .
The many potential clinical applications of these new parameters have especially improved the differential diagnosis and follow-up of anemia, allowing a more efficient, timely and cost-effective diagnosis, as shown by studies demonstrating that their routine application was helpful for optimizing diagnosis and care pathways [4-6, 9, 10] . RET parameters, such as RET-He, support the quantitative and qualitative evaluation of erythropoiesis, especially the direct assessment of iron available for Hb synthesis [4] [5] [6] 11] . The IRF index may be reliably used in a variety of hematologic conditions [11] [12] [13] , but is especially useful for assessing bone marrow recovery after transplantation and post-chemotherapy [14, 15] . Although the use of these innovative parameters for diagnosis and follow-up of anemia is now supported by solid evidence, no information on their biological variation (BV) and on the related quality specifications has been published so far to the best of our knowledge. In the on-line BV database (BV-DB) hosted on the Westgard website [16] no data are available on BV of many RBC and RET indices, whose measured values are also largely influenced by the analytical technique [5, 6] . In recent years, concerns have also been raised about the reliability of some BV data included in the BV-DB [16] . For example, the calculation of BV has often been based on data obtained in publications using a previous generation of analytical methods, and hence characterized by performance characteristics that are now very different from those of the currently available instrumentation. In other cases BV data have been calculated from studies characterized by inaccurate experimental design, especially regarding pre-analytical and analytical procedures, or for the use of an unsuitable approach for data analysis [17] . As a paradigmatic example, the RET count quality specifications published by Sandberg et al. [18] are based on two hematological analyzers which are no longer available in the market. Notably, the importance of obtaining accurate and updated BV indices is also necessary for calculating the reference change value (RCV) [19] [20] [21] .
The XN-module (Sysmex Kobe, Japan) measures conventional hematologic CBC parameters (i.e. RBC, Hb, hematocrit [HT], MCH, MCHC, MCV, RET absolute [#] and percent [%], IRF), along with new parameters such as RET hemoglobin equivalent (RET-He), microcytic-(Micro-R) and macrocytic-RBC (Macro-R), hypochromic-(HYPO-He), hyperchromic-RBC (HYPER-He) and RBC Fragment (FRC) [22] .
Therefore, the aim of this study was to assess the short-and medium-term BV, the RCV and the analytical performance specifications (APS) of conventional and innovative RBC and RET parameters. The study protocol, the analytical measurements and the statistical analysis were carried out according to the current recommendations of the European Federation for Clinical Chemistry and Laboratory Medicine (EFLM) [23] [24] [25] [26] .
Materials and methods
The protocol used to collect peripheral blood samples, the health status and the inclusion/exclusion criteria of the study population have all been previously described elsewhere [27, 28] (Supplemental Data, Figure A) .
Sample collection and handling
Briefly, the study design was designed as follows: a) Medium-term BV arm: 21 subjects (12 females and nine males; age ≥18 years; Caucasian origin). Blood was collected for five consecutive weeks, during the same day of the week (i.e. on Wednesday).
b) Short-term BV arm: 22 subjects (10 females and 12 males; age ≥18 years; Caucasian origin). Blood was collected for five consecutive working days. All the CBC and RET parameters were assessed. Therefore, the final study population consisted of 43 subjects (21 males and 22 females, aged 18-64 years old) (Supplemental Data, Table A ) [27, 28] .
All volunteers filled in a questionnaire during enrolment, which was designed for verifying their health status and collecting information about lifestyle [23] [24] [25] [26] [27] [28] . Additional exclusion criteria were defined according to laboratory testing carried out during the first blood collection [25, 26] . The numbers of subjects, samples and replicates, as previously published [27, 28] , were chosen according to the criteria suggested by Røraas et al. [29] for accurate estimation of within-subject BV (CV I ) applied to RBC and RET parameters directly measured by the hematological analyzer (i.e. Hb, RBC, RET). Blood collections were performed early in the morning, between 8:00 and 8:30 AM, by an expert phlebotomist, always from the same arm, using a straight-needle venipuncture with 20 gauge needles (VACUETTE ® , Greiner bio-one, Kremsmunster, Austria). The blood for CBC or clinical chemistry testing was drawn into evacuated blood tubes containing K 3 EDTA (Becton Dickinson, Franklin Lakes, NJ, USA), or in gel separator blood tubes without additives (Becton Dickinson, Franklin Lakes, NJ, USA), respectively. All subjects were maintained in a sitting position for not less than 5 min before venipuncture. 9.8 (6.7-18.0) BV, biological variation; CV A , analytical variation; CV I , within-subject biological variation; CV G , between-subject biological variation. The results show significant differences between males and females; b the results show significant differences between medium-term and short-term arms.
The study was approved by the Ethical Committee of the Papa Giovanni XXIII Hospital and was carried out in accordance with the Declaration of Helsinki, under the terms of the relevant local legislation.
Laboratory measurements
The CBC, including the assessment of platelets indices, was performed using the XN-module (Sysmex Co., Kobe, Japan) with App PLT-F and App RET [22] . The analyzer uses a combination of flow cytometry, impedance technique and/or fluorescence. All samples were analyzed in duplicate, within 1 h from blood collection, using the same analyzer and an identical lot of reagents. The quality of data obtained throughout the study period was validated by regularly performing internal quality controls, using three levels of specific quality control material (XN-CHECK levels 1, 2 and 3; Streck Laboratories Inc., Omaha, NE, USA).
Statistical analysis
Outlier identification and exclusion was carried out on replicates. Homogeneity of analytical imprecision (between-replicates) and CV I were verified using Bartlett [28] and Cochran [29] tests, respectively. Normality of residuals was verified with the Shapiro-Wilk test [30] . Data analysis was based on the calculation of the CV-ANOVA, an ANOVA preceded by CV-transformation [31] . The Dixon-Reed criterion [32] was used for identifying outliers between individual mean values. The steady-state situation was verified by performing a linear regression for each measurand on the pooled mean group concentration during the whole duration of the study, whilst larger individual systematic changes would be detected by the homogeneity test of the CV I .
A first separate analysis of the data set obtained from both sexes was performed in either arm of the study. Significance of differences of CV I and between-subject BV (CV G ) was assessed in subgroups by calculating the overlap of individual 95% confidence interval (CI).
The BV data was applied for calculating RCV [33] [34] [35] [36] and APS for imprecision (CV APS ), bias (B APS ) and total allowable error (TE APS ) for desirable targets. The following criteria were applied: CV APS = ½ all subjects 
Results
The medium-term BV (first arm of the study) could be calculated in 21 subjects, thus averaging 105 measurements carried out in duplicate. The number of replicates, samples The mean value of MCH, Micro-R, RET%, IRF, LRF and MRF in both genders and both arms of the study displayed a constant overlap of 95% CIs between women and men (Supplementary Table D ). The BV of the HYPO-He, HYPERHe, HFR and FRC parameters could not be calculated in both arms of study because the values of all these parameters approximated zero in healthy subjects.
The mean value, analytical variation (CV A ), CV I and CV G are shown in Tables 1 and 2 . The results have been partitioned between male and female groups only for parameters without significant overlap of 95% CIs. In Supplementary Tables D and E, CV A , CV I and CV G are shown for all subjects, as well as for male and female subgroups, in both arms of the study.
The between-sexes distributions of CV I for RBC, Hb, RDW-CV and RDW-SD are shown in Figures 1 and 2 for the medium-term arm of the study, whilst the distributions of CV I for RET%, are shown in Figure 2 for both the medium-and short-term arms of the study. No significant differences could be observed for CV A s calculated in both the short-and medium-term arms of the study (Tables 1 and 2 ). The CV I s was comprised between 0.2% for MCH and 16.4% for IRF in the medium-term arm of the study, and between 0.2% for MCH and 10.7% for IRF in the short-term arm, respectively. The CV I s of calculated RBC parameters, in the short-and medium-term BV arms, displayed a modest and non significant difference, with 95% CIs always overlapping. Nevertheless, RDW-CV and Micro-R in all subjects, RDW-SD in the female group and MCV in both female and male groups displayed CV I s in the medium-term arm always higher compared to those calculated in the shortterm arm. The CV I s calculated in the medium-and shortterm arms displayed significant difference and no 95% CI overlap between women and men for only RBC and Hb in the medium-term arm. For these two exceptions, the CV I s in women were found to be higher than in men ( Table 1) . The CV I s calculated in the medium-and short-term arms for RET parameters displayed significant differences. The CV I s of the short-term BV arm were found to be always lower than those in the medium-term arm. No differences could be observed between the sexes. Interestingly, although the mean values, CV I and CV G of RDW-CV displayed a constant overlap between genders in both arms of the study, RDW-SD displayed similar CV I and CV G but different mean values. The CV G values were comprised between 0.9% for MCHC and 66.6% for Micro-R in the medium-term arm of the study, and between 1.4% for MCHC and 43.6% for IRF in the short-term arm (Tables 1 and 2 ). The CV G s, calculated in the short-and medium-term arms displayed a modest and non significant difference for RBC parameters, with 95% CIs always overlapping, except for Micro-R in both the female and male groups. The Micro-R CV G s was hence higher in the medium-compared to the short-term arm (Supplementary Table D) . The CV G s calculated in the short-and medium-term arms for RET parameters also displayed a modest and non significant difference, with 95% CIs always overlapping. The CV G s calculated in mediumand short-term BV arms displayed significant difference and no 95% CI overall between women and men for only RET-He in short-term arm. For this exception, CV G s in women were found to be higher than in men ( Table 2) .
The values of both APS and RCV are shown in Tables 3  and 4 . B APS and TE APS were similar in both arms of the study, whilst some differences could be appreciated for CV APS . The values of RCV between genders were similar for all parameters, in both arms of the study, except for RBC and Hb between the females and males groups and MCV, RDW-CV, Micro-R between the medium-and shortterm arms of the study (Table 3 ). In Supplementary Tables F and G, the values of both APS and RCV are shown for all subjects, as well as for male and female subgroups, in both arms of study.
Discussion
The integrated analysis of traditional and innovative RBC and RET indices measured with the new generation of hematologic analyzers is a rapid, relatively inexpensive diagnostic perspective for the differential diagnosis and follow-up of anemia and of many other pathological conditions needing bone marrow erythropoiesis assessment [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . Therefore, calculation of BV for these parameters should be considered an essential aspect not only for evaluating the analytical performance of hematological analyzers, but also for enabling accurate data interpretation and appropriate clinical management [19, 21, [35] [36] [37] .
Although, the mean values of most hematological parameters obtained in the female group were expectedly lower than those in the male group, the CV I s surprisingly do not show a similar trend. In fact, significant differences between genders could only be observed for RBC and for Hb in the medium-term arm of the study (Table 1) , with women CV I s always higher than those calculated in men. This data can be likely explained by two aspects, i.e. the study design based on 5-week assessment and the age of the women included in this study (i.e. 10 out of the 12 were at the fertile age).
It is also not surprising that the CV I s of RET parameters in the short-term arm were always lower than those calculated in the medium-term arm, as RETs have an average life span of 2-3 days [4] [5] [6] and their measurement is hence largely influenced by sudden changes in erythropoiesis, which do not usually occur in healthy subjects with regular lifestyle such as those enrolled in Range minimum-maximum and median value (hyphen) for each individual ordered by experimental phase. Dashed lines point out the 5th and 95th percentiles and the continuous lines the median value (±CI) for "medium-term" and "short-term" of RET% parameter this study. Nevertheless, the CV I s that we have calculated for all parameters in both sexes, either in the medium-or short-term arms, were found to be lower than, or in rare cases (i.e. Ht and MRF) similar to those previously published by Sandberg et al. [18] or to those available in the on-line BV-DB [16] . Although the BV data for RBC and RET parameters in our study were lower than those of the BV-DB [16] , a direct comparison is unfeasible as previous data was obtained years ago, using outdated hematological analyzers, and whose analytical performance is not as good as that of the current instrumentation [18, [39] [40] [41] [42] [43] [44] . Moreover, data reported in the BV-DB [16] were assessed by pooling information obtained with different analyzers, various analytical techniques, heterogeneous protocols and throughout different sampling periods [18, [39] [40] [41] [42] [43] [44] . The interesting difference observed between RDW-CV and RDW-SD further supports the suggestion to use the former measure for expressing the degree of anisocytosis, as the calculation of RDW as CV may allow obtaining a more standardized and harmonized means of data reporting, especially using instrumentation based on different analytical techniques [45] . Although many RBC and RET parameters are strictly analyzer-and technology-dependent, the standard parameters (i.e. RBC, Hg, Ht, MCH, MCHC, MCV and RET#) are an exception and their BV findings may also be translated to analyzer produced by other manufacturers, as attested by data of external quality assessment showing good agreement between the different technologies. Notably, the statistical power of the study for assessment of medium-and short-term BV of RBC and RET parameters was always ≤1.00 (i.e. the ratio CV A /CV I was always ≤1.0) as suggested by Røraas et al. [25] , except for MCH in both arms of study, and MCHC in the short-term arm. The CV G s do not display substantial differences between the two arms of the study, whilst significant differences between genders could only be observed for RET-He in the shortterm arm.
The values of RCVs calculated for RBC, Hb, RDW-CV, MCV Micro-R displayed some differences between sexes and between arms in this study (Tables 3 and 4 ). For these parameters it is hence advisable to use RCVs calculated according to the time of monitoring and/or differentiated by sex. In women it may be especially advisable to also consider the impact of the age, because the kinetics of RBCs production changes in parallel with aging. A possible limitations of this study is the relatively narrow age range of the female volunteers enrolled (i.e. 10 out of the 12 were in fertile age) and additional studies may hence be needed to verify the possible use of this data in postmenopausal women.
As regards the analytical goals, we suggest the use of the most stringent targets found in the short-term arm of this study.
In conclusion, this study has allowed defining the BV of many RBC and RET parameters measured with the new hematology analyzer Sysmex XN. This information is essential for setting quality goals, for accurately defining reference ranges and for establishing the significance of changes during longitudinal monitoring of patients' data based, for example, on the RCV.
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